# Affera

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/affera

- Industry: Medical Devices & Equipment
- Headquarters: Newton, US
- Website: www.affera.com
- Latest round: Series A (Feb 1, 2017)
- Investors on record: 2

## About

Based in Newton, U.S., and founded in 2013, Affera, Inc., also known as Affera, is a MedTech company that engages in delivering technological solutions, and devices, for the treatment of cardiac arrhythmia. In December 2021, the company raised USD 75 million in Series C round from new investor Bain Capital, and in January 2022, Medtronic Diabetes PLC, a portfolio company of Blackstone, agreed to acquire Affera, Inc. for USD 925 million. As of 2022, the company is being led by its founder and CEO, Doron Harlev (co-founder of Rhythmia Medical).

Affera, Inc.’s team of researchers and engineers develops and offers Sphere-9™, a catheter-based cardiac ablation (removal of faulty tissues in the heart to restore normal heart rhythm) technology and Affera Prism-1™, an integrated platform for cardiac mapping and navigation, which are designed to assist cardiologists in the diagnosis and treatment of cardiac arrhythmia (irregular heartbeat), thereby enhancing the patient outcomes.

The company intends to use the proceeds from December 2021 funding to further develop its platform and execute IDE (Investigational Device Exemption) trials, and clinical programs, as well as to scale up its manufacturing and operations. The acquisition by Medtronic Diabetes PLC is expected to close in the first half of Medtronic’s fiscal year 2023.

## Funding rounds

- Series A, Feb 1, 2017 — Norwich Ventures, BAMCAP

## Investors

- Norwich Ventures (https://capitalatlas.ai/funds/norwich-ventures) — Series A
- BAMCAP (https://capitalatlas.ai/funds/bamcap) — Series A